Interleukin-6 but not tumour necrosis factor-alpha predicts survival in patients with advanced cancer

Supportive Care in Cancer

Volumn 21, Issue 11, 2013, Pages 3071-3077

  Suh, Sang Yeon ^a,b   Choi, Youn Seon ^c   Yeom, Chang Hwan ^d   Kwak, Sang Mi ^e   Yoon, Ho Min ^c   Kim, Dae Gyun ^f   Koh, Su Jin ^g   Park, Jeanno ^h   Lee, Myung Ah ⁱ   Lee, Yong Joo ⁱ   Seo, Ah Ram ^a   Ahn, Hong Yup ^a   Yim, Eunji ^b  

^a Dongguk University   (South Korea)

^b Dongguk University   (South Korea)

^c Korea University College of Medicine   (South Korea)

^d Ucell Clinic   (South Korea)

^e Sungkyunkwan University School of Medicine   (South Korea)

^f Bupyeong gu   (South Korea)

^g Good Samaritan Hospital   (South Korea)

^h Bobath Memorial Hospital   (South Korea)

ⁱ The Catholic University of Korea   (South Korea)

Author keywords

Advanced cancer; Interleukin 6; Survival; Tumour necrosis factor alpha

Indexed keywords

CYTOKINE; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CACHEXIA; CANCER CENTER; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; FEMALE; FUNCTIONAL STATUS; HOSPICE; HUMAN; INFECTION; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; SOUTH KOREA; SURVIVAL TIME; TERMINAL CARE;

AGED; ANOREXIA; CACHEXIA; FEMALE; HOSPICES; HUMANS; INTERLEUKIN-6; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASMS; PALLIATIVE CARE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REPUBLIC OF KOREA; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84885572117     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-013-1878-4     Document Type: Article

References (44)

1. Bataille R, Barlogie B, Lu ZY, Rossi JF, Lavabre-Bertrand T, Beck T, Wijdenes J, Brochier J, Klein B (1995) Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 86:685-691
2. Bigbee WL, Grandis JR, Siegfried JM (2007) Multiple cytokine and growth factor serum biomarkers predict therapeutic response and survival in advanced-stage head and neck cancer patients. Clin Cancer Res 13:3107-3108
3. Bossola M, Muscaritoli M, Bellantone R, Pacelli F, Cascino A, Sgadari A, Battaglia F, Piccioni E, Scambia G, Doglietto GB, Rossi Fanelli F (2000) Serum tumour necrosis factor-alpha levels in cancer patients are discontinuous and correlate with weight loss. Eur J Clin Investig 30:1107-1112
4. Chang KP, Chang YT, Wu CC, Liu YL, Chen MC, Tsang NM, Hsu CL, Chang YS, Yu JS (2011) Multiplexed immunobead-based profiling of cytokine markers for detection of nasopharyngeal carcinoma and prognosis of patient survival. Head Neck 33(6):886-897
5. Chang CH, Hsiao CF, Yeh YM, Chang GC, Tsai YH, Chen YM, Huang MS, Chen HL, Li YJ, Yang PC, Chen CJ, Hsiung CA, Su WC (2013) Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy. Int J Cancer 132(9):1977-1985
6. Choi YS, Lee J, Park JN, Lee MA, Yeom CH, Jang SK (2003) Reliability and validity of the evaluation of Korean cancer pain assessment tool (K-CPAT). Korean J Hosp Palliat Care 6:152-163
7. Di Nisio M, Niers TM, Reitsma PH, Buller HR (2005) Plasma cytokine and P-selectin levels in advanced malignancy: prognostic value and impact of low-molecular weight heparin administration. Cancer 104:2275-2281
8. Emilie D, Wijdenes J, Gisselbrecht C, Jarrousse B, Billaud E, Blay JY, Gabarre J, Gaillard JP, Brochier J, Raphael M (1994) Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: effect on lymphoma growth and on B clinical symptoms. Blood 84:2472-2479
9. Ferroni P, Riondino S, Portarena I, Formica V, La Farina F, Martini F, Massimiani G, Palmirotta R, Guadagni F, Roselli M (2012) Association between increased tumor necrosis factor alpha levels and acquired activated protein C resistance in patients with metastatic colorectal cancer. Int J Colorectal Dis 27(12):1561-1567
10. Grim-Stieger M, Keilani M, Mader RM, Marosi C, Schmidinger M, Zielinski CC, Fialka-Moser V, Crevenna R (2008) Serum levels of tumour necrosis factor-alpha and interleukin-6 and their correlation with body mass index, weight loss, appetite and survival rate - preliminary data of Viennese outpatients with metastatic cancer during palliative chemotherapy. Eur J Cancer Care (Engl) 17:454-462
11. Guo Y, Xu F, Lu T, Duan Z, Zhang Z (2012) Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 38:904-910
12. Haddad E, Paczesny S, Leblond V, Seigneurin JM, Stern M, Achkar A, Bauwens M, Delwail V, Debray D, Duvoux C, Hubert P, Hurault de Ligny B, Wijdenes J, Durandy A, Fischer A (2001) Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial. Blood 97:1590-1597
13. Hamed EA, Zakhary MM, Maximous DW (2012) Apoptosis, angiogenesis, inflammation, and oxidative stress: basic interactions in patients with early and metastatic breast cancer. J Cancer Res Clin Oncol 138:999-1009
14. Hong DS, Angelo LS, Kurzrock R (2007) Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer 110:1911-1928
15. Illman J, Corringham R, Robinson D Jr, Davis HM, Rossi JF, Cella D, Trikha M (2005) Are inflammatory cytokines the common link between cancer-associated cachexia and depression? J Support Oncol 3:37-50
16. Korostoff A, Reder L, Masood R, Sinha UK (2011) The role of salivary cytokine biomarkers in tongue cancer invasion and mortality. Oral Oncol 47:282-287
17. Kwak SM, Choi YS, Yoon HM, Kim DG, Song SH, Lee YJ, Yeom CH, Koh SJ, Park J, Lee MA, Suh SY (2012) The relationship between interleukin-6, tumor necrosis factor-alpha, and fatigue in terminally ill cancer patients. Palliat Med 26:275-282
18. Lamont EB, Christakis NA (2003) Complexities in prognostication in advanced cancer: "to help them live their lives the way they want to". JAMA 290:98-104
19. Llobera J, Esteva M, Rifa J, Benito E, Terrasa J, Rojas C, Pons O, Catalan G, Avella A (2000) Terminal cancer. duration and prediction of survival time. Eur J Cancer 36:2036-2043
20. Llovet JM, Pena CE, Lathia CD, Shan M, Meinhardt G, Bruix J (2012) Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 18:2290-2300
21. Loprinzi CL, Johnson ME, Steer G (2000) Doc, how much time do I have? J Clin Oncol 18:699-701
22. Lukaszewicz-Zajac M, Mroczko B, Kozlowski M, Niklinski J, Laudanski J, Szmitkowski M (2012) Higher importance of interleukin 6 than classic tumor markers (carcinoembryonic antigen and squamous cell cancer antigen) in the diagnosis of esophageal cancer patients. Dis Esophagus 25:242-249
23. Maltoni M, Caraceni A, Brunelli C, Broeckaert B, Christakis N, Eychmueller S, Glare P, Nabal M, Vigano A, Larkin P, De Conno F, Hanks G, Kaasa S (2005) Prognostic factors in advanced cancer patients: evidence-based clinical recommendations - a study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol 23:6240-6248
24. Maltoni M, Scarpi E, Pittureri C, Martini F, Montanari L, Amaducci E, Derni S, Fabbri L, Rosati M, Amadori D, Nanni O (2012) Prospective comparison of prognostic scores in palliative care cancer populations. Oncologist 17:446-454
25. Martin F, Santolaria F, Batista N, Milena A, Gonzalez-Reimers E, Brito MJ, Oramas J (1999) Cytokine levels (IL-6 and IFN-gamma), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine 11:80-86
26. Moreau P, Harousseau JL, Wijdenes J, Morineau N, Milpied N, Bataille R (2000) A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma. Br J Haematol 109:661-664
27. Moses AG, Maingay J, Sangster K, Fearon KC, Ross JA (2009) Pro-inflammatory cytokine release by peripheral blood mononuclear cells from patients with advanced pancreatic cancer: relationship to acute phase response and survival. Oncol Rep 21:1091-1095
28. Okuyama T, Wang XS, Akechi T, Mendoza TR, Hosaka T, Cleeland CS, Uchitomi Y (2003) Validation study of the Japanese version of the brief fatigue inventory. J Pain Symptom Manag 25:106-117
29. Penna F, Minero VG, Costamagna D, Bonelli G, Baccino FM, Costelli P (2010) Anti-cytokine strategies for the treatment of cancer-related anorexia and cachexia. Expert Opin Biol Ther 10:1241-1250
30. Pirisi A (2000) US researchers find key link in muscle-wasting syndrome. Lancet 356:1249
31. Reyes-Gibby CC, Wu X, Spitz M, Kurzrock R, Fisch M, Bruera E, Shete S (2008) Molecular epidemiology, cancer-related symptoms, and cytokines pathway. Lancet Oncol 9:777-785
32. Scheede-Bergdahl C, Watt HL, Trutschnigg B, Kilgour RD, Haggarty A, Lucar E, Vigano A (2012) Is IL-6 the best pro-inflammatory biomarker of clinical outcomes of cancer cachexia? Clin Nutr 31:85-88
33. Seruga B, Zhang H, Bernstein LJ, Tannock IF (2008) Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer 8:887-899
34. Statistics Korea (2012) Causes of death statistics in 2011
35. Su C, Zhou C, Zhou S, Xu J (2011) Serum cytokine levels in patients with advanced non-small cell lung cancer: correlation with treatment response and survival. Med Oncol 28:1453-1457
36. Suh SY (2007) Survival prediction of terminally ill cancer patients. Korean J Hosp Palliat Care 10:171-177
37. Suh SY, Ahn HY (2007) Lactate dehydrogenase as a prognostic factor for survival time of terminally ill cancer patients: a preliminary study. Eur J Cancer 43:1051-1059
38. Suh SY, Ahn HY (2007) A prospective study on C-reactive protein as a prognostic factor for survival time of terminally ill cancer patients. Support Care Cancer 15:613-620
39. Suh SY, Choi YS, Shim JY, Kim YS, Yeom CH, Kim D, Park SA, Kim S, Seo JY, Kim SH, Kim D, Choi SE, Ahn HY (2010) Construction of a new, objective prognostic score for terminally ill cancer patients: a multicenter study. Support Care Cancer 18:151-157
40. Toiyama Y, Fujikawa H, Kawamura M, Matsushita K, Saigusa S, Tanaka K, Inoue Y, Uchida K, Mohri Y, Kusunoki M (2012) Evaluation of CXCL10 as a novel serum marker for predicting liver metastasis and prognosis in colorectal cancer. Int J Oncol 40:560-566
41. Trompet S, de Craen AJ, Mooijaart S, Stott DJ, Ford I, Sattar N, Jukema W, Westendorp RG (2009) High innate production capacity of proinflammatory cytokines increases risk for death from cancer: results of the PROSPER study. Clin Cancer Res 15:7744-7748
42. Utsumi K, Takai Y, Tada T, Ohzeki S, Fujiwara H, Hamaoka T (1990) Enhanced production of IL-6 in tumor-bearing mice and determination of cells responsible for its augmented production. J Immunol 145:397-403
43. World Health Organization (2011) The 10 leading causes of death by broad income group. WHO, Geneva
44. Yun YH, Wang XS, Lee JS, Roh JW, Lee CG, Lee WS, Lee KS, Bang SM, Mendoza TR, Cleeland CS (2005) Validation study of the Korean version of the brief fatigue inventory. J Pain Symptom Manag 29:165-172